35 972 R.P.,
4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione,
4-methyl-PDT,
5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione,
oltipraz,
RP 35972,
Oltipraz,
64224-21-1,
4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione,
RP 35972,
Oltiprazum,
CCRIS 4048,
NSC 347901,
Oltipraz [INN],
4-Methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione,
RP-35,972,
BRN 0978110,
Oltiprazum [INN-Latin],
UNII-6N510JUL1Y,
3H-1,2-DITHIOLE-3-THIONE, 4-METHYL-5-PYRAZINYL-,
EINECS 264-736-6,
MFCD00868499,
5-(2-Pyrazinyl)-4-methyl-1,2-dithiole-3-thione,
6N510JUL1Y,
C8H6N2S3,
CHEBI:77319,
4-Methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione,
4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione,
NSC347901,
AK154201,
4-methyl-5-pyrazin-2-yldithiole-3-thione,
4-methyl-5-pyrazin-2-yl-dithiole-3-thione,
4-methyl-5-pyrazin-2-yl-3H-1,2-dithiole-3-thione,
OLT,
4-methyl-5-(pyrazin-2-yl)-1,2-dithiole-3-thione,
AC1L2HUC,
5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione,
MLS006011663,
SCHEMBL241164,
CHEMBL178459,
ZINC1852,
DTXSID7021079,
CTK8G2170,
3H-1, 4-methyl-5-pyrazinyl-,
EX-A646,
CKNAQFVBEHDJQV-UHFFFAOYSA-N,
HMS2090F09,
Pharmakon1600-01502317,
BCP16064,
4440AJ,
BDBM50418081,
DL-106,
NSC759840,
Oltipraz, >=98% (HPLC), powder,
AKOS015950809,
AN-5398,
API0003679,
AS-7036,
CCG-213819,
CS-5412,
DB12539,
FCH1327698,
LS-7628,
NE63013,
NSC-347901,
NSC-759840,
SB17336,
TRA0008507,
KS-0000184A,
AJ-08101,
CC-33325,
HY-12519,
NCI60_003092,
RP-35972,
SMR001550500,
ZB000424,
AB1004854,
B5958,
FT-0630745,
S7864,
A13164,
AB01275510-01,
AB01275510_02,
C-12905,
SR-05000001517,
SR-05000001517-1,
4-methyl-5-(2-pyrazinyl)-3h-1,2-dithiole-3-thione,
oltipra2,
4-methyl-PDT,
OXCARBAZEPINE,
D0W4NM,
C8-H6-N2-S3,
CID47318,
CB-1400,
35 972 R.P.,
Oltipraz (mucositis/radiation sickness/cancer),
C026209,
Oltipraz (mucositis/radiation sickness/cancer), Canopus Biopharma,
Syntheticdithiolethione (oral, acute radiation syndrome/mucositis/cancer), Canopus,
28721-07-5,